Novo Nordisk Reports Improved Results of Oral Semaglutide in PIONEER 9 Study in Patients with Type-2 Diabetes (T2D)

 Novo Nordisk Reports Improved Results of Oral Semaglutide in PIONEER 9 Study in Patients with Type-2 Diabetes (T2D)

Novo Nordisk Reports Improved Results of Oral Semaglutide in PIONEER 9 Study in Patients with Type-2 Diabetes (T2D)

Shots:

  • The P-IIIa PIONEER 9 trial involves assessing of Oral Semaglutide (3, 7,14 mg, qd) vs Victoza (0.9 mg liraglutide) vs PBO in 243 Japanese adults in ratio (1:1:1:1:1) with T2D treated with diet and exercise alone or in addition to an oral anti-diabetic drug as monothx
  • Results: reduction in HbA1c @26 wks. (1.1%, 1.5% ,1.7% vs 1.4% vs 0.1%); greater reductions in HbA1c @52 wks. (0.9%, 1.3%, 1.5% vs 1.1% vs 0.5%); Achieve target treatment (50%, 67% ,80% vs 49% vs 12%); reduction in body weight (0.0, 0.6, 2.8 vs 0.4 vs 1.0 kg); safe & well-tolerated
  • Semaglutide is an oral qd GLP-1 analogue indicated for reduction in cardiovascular risk and death in T2D patients

Click here to read full press release/ article | Ref: Novo Nordisk | Image:Borsen

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post